FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind [CBS News]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CBS News
The U.S. Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly's oral drug , orforglipron, is still under review. Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness. In recent years, Novo Nordisk's injectable Wegovy and Lilly's Zepbound have revolutionized obesity treatment globally and in the U.S., where 100 million people have the chronic disease. The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said. About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF , a nonprofit health policy research group. But many more have trouble affording the costly shots. "There's an entire demographic
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy weight loss pill from Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy weight-loss pill from Novo Nordisk [USA TODAY]USA TODAY
- US regulators approve Wegovy pill for weight loss [Yahoo! Finance Canada]Yahoo! Finance Canada
- US Approves First GLP-1 Pill For Weight Loss: Novo Nordisk [Barron's]Barrons
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website